Literature DB >> 8085960

Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin.

B R Saran1, A M Maguire, C Nichols, I Frank, R W Hertle, A J Brucker, S Goldman, M Brown, B Van Uitert.   

Abstract

OBJECTIVE: Iridocyclitis has been identified as a dosage-dependent side effect in patients with the acquired immunodeficiency syndrome (AIDS) who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin. We reviewed cases of acute hypopyon uveitis occurring in patients with AIDS to establish whether there was an association.
DESIGN: Retrospective case series.
SETTING: Outpatient clinic and inpatient hospital-based ophthalmology referral practice and infectious disease specialty service. PATIENTS: Seven patients with AIDS, aged 10 to 40 years, presenting with acute unilateral hypopyon mimicking infectious endophthalmitis. MAIN OUTCOME MEASURES: Findings from complete ophthalmological evaluation and ancillary laboratory testing.
RESULTS: At the time of presentation, all seven patients were receiving treatment for MAC infection with rifabutin (dosage range, 300 to 600 mg/d) and clarithromycin. Results of microbiological investigations in five patients were negative. Iridocyclitis became bilateral in all seven patients, and hypopyon developed in the contralateral eye in five of seven patients. Hypopyon resolved rapidly with intensive topical corticosteroid therapy. Residual inflammation responded to topical corticosteroids with or without reduction of the rifabutin dosage.
CONCLUSIONS: Concomitant use of rifabutin, clarithromycin, and fluconazole may precipitate hypopyon uveitis in patients with AIDS being treated for MAC infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085960     DOI: 10.1001/archopht.1994.01090210043015

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia.

Authors:  B Golchin; K McClellan
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients.

Authors:  P Kelleher; M Helbert; J Sweeney; J Anderson; J Parkin; A Pinching
Journal:  Genitourin Med       Date:  1996-12

Review 3.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

Review 4.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

Review 5.  Drug-induced uveitis. Incidence, prevention and treatment.

Authors:  F W Fraunfelder; J T Rosenbaum
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

Review 6.  Diagnostic dilemmas in retinitis and endophthalmitis.

Authors:  J L Davis
Journal:  Eye (Lond)       Date:  2011-11-25       Impact factor: 3.775

Review 7.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

8.  Treatment of neuro-ophthalmologic manifestations of tuberculosis.

Authors:  Susannah Mistr; Pamela S Chavis
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.972

9.  Uveitis in a patient receiving rifabutin for Crohn's disease.

Authors:  O Awotesu; T Missotten; M C Pitcher; W A Lynn; S Lightman
Journal:  J R Soc Med       Date:  2004-09       Impact factor: 18.000

10.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.